Table 3 Distribution of CYP2 genotypes and risk of neoadjuvant chemotherapy resistance developing in breast cancer patients
Polymorphism | Genotype | Positive neoadjuvant chemotherapy response | Negative neoadjuvant chemotherapy response | OR | CI (95%) | p | ||
|---|---|---|---|---|---|---|---|---|
n | % | n | % | |||||
CYP2B6*5 C1459T | CC | 205 | 82.66 | 9 | 90.00 | 1.89 | 0.25 - 84.64 | 0.99 |
CT | 37 | 14.92 | 1 | 10.00 | 1.13 | 0.54 - 2.40 | 0.99 | |
TT | 6 | 2.42 | 0 | 0.00 | 0.63 | 0.01 - 4.82 | 0.99 | |
CYP2C8*2 T805A | TT | 243 | 99.59 | 10 | 100.00 | 0.04 | 0.01 - 3.55 | 0.08 |
TA | 1 | 0.41 | 0 | 0.00 | 24.30 | 0.28 - 1914.18 | 0.08 | |
AA | 0 | 0.00 | 0 | 0.00 | * | |||
CYP2C8*3 G416A + A1196G | GG | 203 | 82.19 | 6 | 60.00 | 0.33 | 0.07 - 1.64 | 0.09 |
GA | 44 | 17.81 | 4 | 40.00 | 3.08 | 0.61 - 13.53 | 0.09 | |
AA | 0 | 0.00 | 0 | 0.00 | * | |||
CYP2C9*2 C430T | CC | 204 | 82.26 | 5 | 50.00 | 0.22 | 0.05 - 0.99 | 0.02 |
CT | 44 | 17.74 | 5 | 50.00 | 4.64 | 1.01 - 20.91 | 0.02 | |
TT | 0 | 0.00 | 0 | 0.00 | * | |||
CYP2C9*3 A1075C | AA | 211 | 84.40 | 8 | 80.00 | 0.74 | 0.14 - 7.41 | 0.66 |
AC | 36 | 14.40 | 1 | 10.00 | 0.66 | 0.01 - 5.03 | 0.99 | |
CC | 3 | 1.20 | 1 | 10.00 | 9.15 | 0.16 - 124.95 | 0.15 | |
CYP2C19*2 G681A | GG | 136 | 54.62 | 8 | 66.67 | 3.32 | 0.64 - 32.61 | 0.19 |
GA | 109 | 43.78 | 2 | 16.67 | 0.32 | 0.03 - 1.66 | 0.20 | |
AA | 4 | 1.61 | 2 | 16.67 | 6.13 | 0.11 - 69.01 | 0.20 | |
CYP2C19*3 G636A | GG | 241 | 97.97 | 10 | 100.00 | 0.21 | 0.02 - 10.78 | 0.23 |
GA | 5 | 2.03 | 0 | 0.00 | 4.82 | 0.09 - 48.97 | 0.23 | |
AA | 0 | 0.00 | 0 | 0.00 | * | |||